ME Therapeutics Holdings Inc.
METX
CNSX
| 11/30/2024 | 08/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -9.40% | -33.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.31% | -39.83% | |||
| Operating Income | 5.31% | 39.83% | |||
| Income Before Tax | 3.86% | 37.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.86% | 37.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.86% | 37.39% | |||
| EBIT | 5.31% | 39.83% | |||
| EBITDA | 5.61% | 39.85% | |||
| EPS Basic | 3.33% | 37.93% | |||
| Normalized Basic EPS | 5.26% | 37.36% | |||
| EPS Diluted | 3.33% | 38.78% | |||
| Normalized Diluted EPS | 5.26% | 37.36% | |||
| Average Basic Shares Outstanding | -0.02% | 0.43% | |||
| Average Diluted Shares Outstanding | -0.02% | 0.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
